Melero-Martin Juan M, Bischoff Joyce
Vascular Biology Program and Department of Surgery, Children's Hospital, Boston, Harvard Medical School, Boston, Massachusetts, USA.
Methods Enzymol. 2008;445:303-29. doi: 10.1016/S0076-6879(08)03013-9.
Rapid and complete vascularization of ischemic tissues and thick engineered tissues is likely to require vasculogenesis. Therefore, the search for clinically relevant sources of vasculogenic cells and the subsequent development of experimental models of vasculogenesis is of utmost importance. Here, we describe a methodology adapted from the Matrigel plug assay to deliver human blood-derived endothelial progenitor cells (EPCs) and mature smooth muscle cells (SMCs) subcutaneously into immunodeficient mice. One week after implantation, an extensive microvascular network composed of the human EPCs and SMCs is formed within the Matrigel. The presence of human EPC-lined lumens containing host erythrocytes can be seen throughout the implants indicating not only the formation (de novo) of a vascular network, but also the development of functional anastomoses with the host circulatory system. This is a very versatile assay that allows (1) dialing the final microvessel density by varying either the total number of cells in the original cell suspension or the ratio between EPCs and SMCs, (2) studying the effect of substituting another type of perivascular cell for mature SMCs or another type of endothelial cell, (3) tracking each of the implanted cell types by labeling (e.g., GFP tagging) prior to implantation, and (4) studying the effect of genetically modifying the cells prior to implantation. Additionally, this assay is relatively simple to perform and it does not require an incision or surgical procedure. This murine model of human vasculogenesis is ideally suited for studies on the cellular and molecular components of microvessel development, pathologic neovascular responses, and for the development and investigation of strategies to enhance neovascularization of engineered human tissues and organs.
缺血组织和厚的工程组织的快速且完全血管化可能需要血管生成。因此,寻找具有临床相关性的血管生成细胞来源以及随后开发血管生成的实验模型至关重要。在此,我们描述了一种从基质胶栓试验改编而来的方法,用于将人血源性内皮祖细胞(EPCs)和成熟平滑肌细胞(SMCs)皮下注射到免疫缺陷小鼠体内。植入一周后,在基质胶内形成了由人EPCs和SMCs组成的广泛微血管网络。在整个植入物中都可以看到含有宿主红细胞的人EPC内衬管腔的存在,这不仅表明血管网络的形成(从头形成),而且还表明与宿主循环系统形成了功能性吻合。这是一种非常通用的试验,它允许:(1)通过改变原始细胞悬液中的细胞总数或EPCs与SMCs之间的比例来调节最终微血管密度;(2)研究用另一种类型的周细胞替代成熟SMCs或另一种类型的内皮细胞的效果;(3)在植入前通过标记(例如,绿色荧光蛋白标记)追踪每种植入的细胞类型;(4)研究在植入前对细胞进行基因改造的效果。此外,该试验相对容易操作,并且不需要切口或手术程序。这种人血管生成的小鼠模型非常适合用于研究微血管发育的细胞和分子成分、病理性新生血管反应,以及用于开发和研究增强工程化人体组织和器官新生血管化的策略。